{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:54:25Z","timestamp":1789239265377,"version":"build-2803163510"},"reference-count":28,"publisher":"Consilium Medicum","issue":"11","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim. To identify risk factors for adverse drug reactions (ADRs) in patients co-infected with multidrug-resistant tuberculosis (MDR-TB), HIV and viral hepatitis C (HCV).\r\nMaterials and methods. The incidence, spectrum, association with medications, and outcomes of ADRs were studied in 132 patients with MDR-TB\/HIV\/HCV receiving antituberculosis and antiretroviral therapy. Statistical methods of data processing were used to identify predictors of ADRs development.\r\nResults. The overall incidence of undesirable ADRs amounted to 67%, severe ADRs of 3\u20134 degrees \u2013 12%. Hepatotoxic (31%), nephrotoxic (18%) and dyspeptic (16%) reactions took the leading place in the spectrum of undesirable ADRs. Among the outcomes of all undesirable ADRs, the vast majority of TB drugs were canceled (61%), and undesirable ADRs were managed only in 6% of cases. Pyrazinamide, para-aminosalicylic acid, injectable aminoglycosides had the most unfavorable safety profile in the studied cohort, which led to their final exclusion from chemotherapy regimens.\r\nConclusion. Independent predictors of any undesirable ADRs were kanamycin, pyrazinamide and para-aminosalicylic acid administration, severe reactions were hepatobiliary disorders, and drug withdrawal due to the development of undesirable ADRs were pyrazinamide and para-aminosalicylic acid administration. Bedaquiline, delamanid, moxifloxacin and ethambutol had the most favorable safety profile in the study cohort. The obtained data allow to form risk groups for the development of ADRs in patients with triple infection, to identify indications for enhanced monitoring and prescription of drug prophylaxis at the start of treatment.<\/jats:p>","DOI":"10.26442\/00403660.2025.11.203451","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T06:29:26Z","timestamp":1766212166000},"page":"920-926","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors for adverse events in patients with multidrug-resistant tuberculosis, HIV-infection and viral hepatitis C"],"prefix":"10.26442","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3383-7723","authenticated-orcid":false,"given":"Anastasiia V.","family":"Kukurika","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Phthisiopulmonology and Infectious Diseases"},{"name":"Moscow Research and Clinical Center for Tuberculosis Control"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18344","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.21292\/2075-1230-2019-97-5-28-40"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.26442\/00403660.2020.08.000762"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21292\/2075-1230-2018-96-11-74-82"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21292\/2075-1230-2020-98-9-56-62"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.21292\/2075-1230-2020-98-1-5-15"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.56871\/MTP.2023.90.21.007"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21292\/2075-1230-2017-95-6-22-29"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.22625\/2072-6732-2017-9-4-126-132"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.22328\/2077-9828-2021-13-1-7-16"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12121394"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.15789\/2220-7619-2019-5-6-787-799"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.31146\/1682-8658-ecg-206-10-25-31"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.21292\/2075-1230-2022-100-1-33-40"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh2017891150-54"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"\u0417\u0438\u043c\u0438\u043d\u0430 \u0412.\u041d., \u041a\u0440\u0430\u0432\u0447\u0435\u043d\u043a\u043e \u0410.\u0412. \u0412\u043b\u0438\u044f\u043d\u0438\u0435 \u044d\u0442\u0438\u043e\u0442\u0440\u043e\u043f\u043d\u043e\u0439 \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u043d\u0430 \u0438\u043c\u043c\u0443\u043d\u043d\u044b\u0439 \u0441\u0442\u0430\u0442\u0443\u0441 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0412\u0418\u0427-\u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0435\u0439 \u0438 \u0442\u0443\u0431\u0435\u0440\u043a\u0443\u043b\u0435\u0437\u043e\u043c. \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u0440\u0445\u0438\u0432. 2015;87(11):37-41 [Zimina VN, Kravchenko AV. Impact of etiotropic therapy on the immune status of patients with HIV infection and tuberculosis. Terapevticheskii Arkhiv (Ter. Arkh.). 2015;87(11):37-41 (in Russian)].","DOI":"10.17116\/terarkh2015871137-41"},{"key":"ref16","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. National Cancer Institute, 2017. Available at: https:\/\/www.ctc. ucl.ac.uk\/TrialDocuments\/Uploaded\/Common%20Terminology %20Criteria%20for%20Adverse%20Events%20(CTCAE)%20v5.0_14092023_0.pdf. Accessed: 05.06.2024."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. PMID:7249508","DOI":"10.1038\/clpt.1981.154"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.34883\/PI.2022.25.5.008"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.21292\/2075-1230-2018-96-3-35-43"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.37489\/0235-2990-2022-67-7-8-40-44"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237534"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248017"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx107"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.33029\/2305-3496-2024-13-2-86-93"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcma.2015.12.006"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820002861"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcma.2017.10.002"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13751"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/633365\/215019","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/633365\/215019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:15:15Z","timestamp":1766574915000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/633365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,12,20]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2025.11.203451","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,20]]}}}